Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIRASOL phase 3 trial of mirvetuximab soravtansine versus investigator's choice chemotherapy in folate receptor alpha-high platinum-resistant ovarian cancer
MOH_2021-01-17_009670Phase 3Recruiting
- Sponsor
- ImmunoGen
- Start
- Jan 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of mirvetuximab soravtansine in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC) (2 arms), sponsored by ImmunoGen. Started Jan 2021; status: recruiting.
02
Drugs
mirvetuximab soravtansine
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on MOH_2021-01-17_009670.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2021-01-17_009670.